摘要
作为一种新型的降糖药物，胰高血糖素样肽（GLP）-1受体激动剂可有效降低血糖、减轻体重。此外，该药可能还具有改善糖尿病患者肾功能，调节水、盐排泄、降低血压等作用。并且，这一保护作用可能是通过其抗炎、抗氧化应激、改善内皮细胞功能实现的。但是，该药物不适用于严重肾脏病变的患者，因此，它是否可以用于预防和治疗糖尿病肾病，目前尚无定论。
As a new antidiabetic medicine, glucagon-like peptide （GLP）-1 receptor agonist can effectively lower blood glucose and reduce body weight. In addition, it may also improve renal function of diabetic patients, regulate water and salt excretion as well as lower blood pressure. This effect may depend on its anti-inflammation, anti-oxidative stress and endothelial function improvement. However, GLP-1 receptor agonist is not suitable for patients with severely injured renal function, and whether or not it can be used to prevent and treat diabetic nephropathy remains unclear.
出处
《国际内分泌代谢杂志》
北大核心
2014年第6期401-403,共3页
International Journal of Endocrinology and Metabolism
